Gefarnate
Chemical compound
- A02BX07 (WHO)
- (2E)-3,7-dimethylocta-2,6-dien-1-yl (4E,8E)-5,9,13-trimethyltetradeca-4,8,12-trienoate
- 51-77-4 Y
- 5282182
- 4445377 N
- 1ISE2Y6ULA
- D01529 Y
- ChEMBL2105085 N
- DTXSID0048636
- Interactive image
- CC(C)=CCC/C(C)=C/CC/C(C)=C/CCC(=O)OC/C=C(C)/CCC=C(C)C
InChI
- InChI=1S/C27H44O2/c1-22(2)12-8-14-24(5)16-10-17-25(6)18-11-19-27(28)29-21-20-26(7)15-9-13-23(3)4/h12-13,16,18,20H,8-11,14-15,17,19,21H2,1-7H3/b24-16+,25-18+,26-20+ N
- Key:ZPACYDRSPFRDHO-ROBAGEODSA-N N
Gefarnate is a drug used for the treatment of gastric ulcers.[1]
It also has been proposed for use in the treatment of dry eye syndrome.[2][3]
References
- ^ Ohta Y, Kobayashi T, Imai Y, Inui K, Yoshino J, Nakazawa S (August 2005). "Effect of gefarnate on acute gastric mucosal lesion progression in rats treated with compound 48/80, a mast cell degranulator, in comparison with that of teprenone". Biol. Pharm. Bull. 28 (8): 1424–30. doi:10.1248/bpb.28.1424. PMID 16079487.
- ^ Peral A, Domínguez-Godínez CO, Carracedo G, Pintor J (April 2008). "Therapeutic targets in dry eye syndrome". Drug News Perspect. 21 (3): 166–76. PMID 18560615.
- ^ Gipson IK, Hori Y, Argüeso P (April 2004). "Character of ocular surface mucins and their alteration in dry eye disease". Ocul Surf. 2 (2): 131–48. doi:10.1016/s1542-0124(12)70149-0. PMID 17216084.[permanent dead link]
- v
- t
- e
Drugs for peptic ulcer and GERD/GORD (A02B)
analogues ("-prost-")
("-prazole")
acid blockers ("-prazan")
- Linaprazan
- Revaprazan
- Soraprazan
- Vonoprazan
- See also: Helicobacter pylori eradication protocols
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This article about an alkene is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e